1. Home
  2. REVB vs NCPL Comparison

REVB vs NCPL Comparison

Compare REVB & NCPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

N/A

Current Price

$1.28

Market Cap

5.1M

Sector

Health Care

ML Signal

N/A

NCPL

Netcapital Inc.

N/A

Current Price

$0.47

Market Cap

5.9M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
REVB
NCPL
Founded
2020
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.1M
5.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
REVB
NCPL
Price
$1.28
$0.47
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
115.5K
125.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$739.37
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$0.37
52 Week High
$3.73
$8.75

Technical Indicators

Market Signals
Indicator
REVB
NCPL
Relative Strength Index (RSI) 47.54 36.72
Support Level $0.77 N/A
Resistance Level $1.38 $0.62
Average True Range (ATR) 0.09 0.06
MACD -0.03 0.00
Stochastic Oscillator 31.03 34.04

Price Performance

Historical Comparison
REVB
NCPL

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About NCPL Netcapital Inc.

Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.

Share on Social Networks: